^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CER-1236
i
Other names: CER-1236
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
CERo Therap
Drug class:
T-cell stimulant
Related drugs:
over1year
Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross presentation. (PubMed, Mol Ther)
We also show that activated CER-1236 T cells exhibit superior cross-presentation ability compared to conventional T cells, triggering E7-specific TCR-T responses in an HLA class I and TLR-2 dependent manner, thereby overcoming the limited antigen presentation capacity of conventional T cells. Therefore, CER-1236 T cells have the potential to achieve tumor control by eliciting both direct cytotoxic effects and indirect-mediated cross-priming.
Journal
|
TLR2 (Toll Like Receptor 2)
|
EGFR mutation
|
CER-1236
Share via
